Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
LLS Applauds Data from Celator Study of CPX-351 for High-Risk AML Patients
White Plains, N.Y. (June 24, 2015) – Interim data released today by Celator Pharmaceuticals regarding its study of CPX-351, a special formulation of …
Who We Are
Surviving AML: The Long Road Back
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
